Las Vegas, NV -- (SBWIRE) -- 12/16/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: Unisys Corporation (NYSE:UIS), Yamana Gold Inc. (USA) (NYSE:AUY), Array Biopharma Inc (NASDAQ:ARRY), ON Semiconductor Corp (NASDAQ:ONNN
Unisys Corporation (NYSE:UIS) managed to keep its gain at 1.26% on below -normal volume of 387,712.00 shares. The stock settled at $29.85 after floating in a range of $29.45 to $29.98. Its latest price has reached market capitalization of $1.31 billion. Its 52-week range has been $15.68 to $30.71. Unisys Corporation provides information technology (IT) services, software, and technology that solve mission-critical problems for clients worldwide. It operates in two segments, Services and Technology.
For How Long UIS will fight for Profitability? Read This Trend Analysis report
Yamana Gold Inc. (USA) (NYSE:AUY) traded up on a volume of 3.66 million, lower than its standard daily volume. Shares have dropped0.35% to $8.69. Over the last twelve months, the stock has lost-50.03% and faced a worst price of $8.31. Yamana Gold Inc. engages in the exploration, development, and production of mineral properties, primarily gold. It also explores for copper, molybdenum, zinc, and silver metals.
For How Long AUY’s Gloss will Attract Investors? Find out via this report
Array Biopharma Inc (NASDAQ:ARRY) settled 2.88% higher at $5 on below -normal volume of 1.41M shares during the last trading day. The stock has its 12-month high at $7.10 and 52-week low price was $3.41. It traded in a range of $4.80 to $5.01 during the last trading day. Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma.
Why Should Investors Buy ARRY After the Recent Fall? Just Go Here and Find Out
In the last trading session, ON Semiconductor Corp (NASDAQ:ONNN) was down on low volume, trading at a volume of 4.32M shares versus its average daily volume of 5.47 million shares. At $7.44, the stock has attained market capitalization of $3.35 billion. ON Semiconductor Corporation designs, manufactures, and markets semiconductor components for electronic systems and products worldwide. The company operates in three segments: Application Products Group, Standard Products Group, and SANYO Semiconductor Products Group.
Why Should Investors Buy ONNN After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)